IDH1 and acute myeloid leukemia: Adverse risk karyotype was present in 13 patients (33%), secondary/therapy-related AML in 8 patients (23%), IDH1/2 mutation in 15/35 (43%), and FLT3-ITD mutation in 7/37 (19%).